Business Context and Reporting Period
This Form 8-K was filed by Nile Therapeutics, Inc. (not Capricor Therapeutics, Inc.) on October 21, 2013. The report details the entry into a material definitive agreement involving the issuance of additional secured convertible promissory notes to existing accredited investors.
Key Financial Metrics
- Debt Issuance: The company issued additional notes with an aggregate principal amount of $120,510.
- Cash Proceeds: The company received aggregate gross proceeds of $102,433 from the issuance.
- Discount: The notes were issued at a discount, with proceeds representing approximately 85% of the principal amount.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, net income, operating cash flow, or liquidity ratios.
Material Changes
This filing represents an amendment to a Convertible Note Purchase Agreement originally entered into on March 15, 2013. Under the original agreement, the company had the capacity to issue up to $500,000 in principal. This transaction adds $120,510 to the outstanding principal under that facility. The additional notes were allocated pro rata among existing holders and carry identical terms to the previously issued notes.
Guidance, Outlook, and Risks
- Transaction Type: The sale of notes constituted a private placement under Section 4(2) of the Securities Act of 1933 and Regulation D.
- Terms: The notes are secured and convertible. Previous amendments (October 3, 2013) modified the conversion price determination method in connection with Change of Control transactions.
- Outlook: The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the debt obligation.
Investor Verification Checklist
- Verify the total outstanding principal amount of the Convertible Notes after this issuance.
- Confirm the specific interest rate and maturity date of the notes, which are not detailed in this specific 8-K text.
- Review the "Change of Control" provisions amended on October 3, 2013, to understand potential dilution scenarios.
- Check subsequent filings for the company's cash burn rate and runway given the reliance on convertible debt financing.